A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in
adults with metastatic cancer. This study includes 3 parts:
- Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types
known to commonly express Ti...
Age: 18 years - 66+
Gender: All
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
This is a multi-site, open-label, non-randomized, single dose study to assess the
clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in
individuals with pathologically confirmed gastric, gastroesophageal junction or
esophageal cancer. Foll...
Age: 18 years - 66+
Gender: All
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe,
tolerable and effective in participants with advanced, or metastatic solid tumors
including urothelial cancer. The study is conducted in two parts - phase Ia
(dose-escalation, dose-o...
Age: 18 years - 66+
Gender: All
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
This phase II trial compares atezolizumab in combination with chemotherapy (docetaxel,
oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for
controlling the growth and/or spreading of the disease in patients with gastric or
gastroesop...
Age: 18 years - 66+
Gender: All
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by
Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
It is necessary that ctDNA test results are linked to clinical outcomes in order to
demon...
Age: 18 years - 66+
Gender: All